Product Images Alendronate Sodium

This is a chart showing the mean percentage change from baseline for a multinational study comparing Alendronate 10 mg versus a placebo over a period of 36 months (3 years). The chart shows results at time points of 0, 12, 24, and 36 months.*

The text represents a figure or a chart showing the mean percentage change from baseline with standard error in a U.S. study comparing the efficacy of 10 mg Alendronate compared to the Placebo over a period of 36 months. It is not possible to accurately evaluate the data without the accompanying figure.*

This text represents a table showing the cumulative incidence in percentage for both Placebo and Alendronate, over a period of time represented in months. There is no other information available.*

This text is a chart displaying the results of a study on the effect of Alendronate 5mg per day on bone mineral density (BMD) in postmenopausal women with osteoporosis. The chart shows the change in BMD from baseline after a 2-year and a 3-year study period compared to a placebo. The BMD percentage changes are shown separately for the lumbar spine, femoral neck, trochanter, and total body.*

The text describes the effect of Alendronate and Etidronate drugs on serum alkaline phosphatase in studies conducted in Paget's Disease of Bone. The text presents the mean % change from baseline for serum alkaline phosphate levels for the drugs and a placebo, 20, -20, -60, and -100, respectively. The studies included a multinational study of Alendronate 40mg/day and a US study of Alendronate 40mg/day. The time frame for the studies was 0, 3, and 6 months.*